Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34
IDH2
azacitidine therapy
histone acetylation
metabolic signature
myelodysplastic syndromes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Apr 2021
30 Apr 2021
Historique:
received:
30
03
2021
revised:
22
04
2021
accepted:
28
04
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
To better understand the molecular basis of resistance to azacitidine (AZA) therapy in myelodysplastic syndromes (MDS) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), we performed RNA sequencing on pre-treatment CD34
Identifiants
pubmed: 33946220
pii: cancers13092161
doi: 10.3390/cancers13092161
pmc: PMC8125503
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Czech Health Research Council
ID : NV16-33485A
Organisme : Ministry of Health of the Czech Republic
ID : 00023736
Organisme : Internal Grant Agency of Palacky University
ID : IGA_LF_2020_005
Références
Oncotarget. 2015 Jun 20;6(17):15265-82
pubmed: 25948775
Cancer Cell. 2016 Jan 11;29(1):104-116
pubmed: 26766592
J Cancer Res Clin Oncol. 2019 Nov;145(11):2835-2843
pubmed: 31506740
Haematologica. 2020 Jan;105(1):22-37
pubmed: 31806687
Blood. 2019 Mar 7;133(10):1096-1107
pubmed: 30670446
Int J Hematol. 2016 Nov;104(5):566-573
pubmed: 27416819
J Proteome Res. 2018 Jan 5;17(1):97-107
pubmed: 29090929
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
J Clin Oncol. 2002 May 15;20(10):2429-40
pubmed: 12011120
Nat Commun. 2018 Sep 12;9(1):3694
pubmed: 30209285
Nat Med. 2018 Dec;24(12):1859-1866
pubmed: 30420752
Nat Cell Biol. 2017 Nov;19(11):1298-1306
pubmed: 29058720
Leuk Lymphoma. 2014 Aug;55(8):1925-9
pubmed: 24138309
Front Oncol. 2020 Jun 24;10:992
pubmed: 32670880
Blood. 2017 Mar 23;129(12):1577-1585
pubmed: 28159741
Cell Rep. 2017 Jul 18;20(3):572-585
pubmed: 28723562
Nat Rev Cancer. 2015 Mar;15(3):166-80
pubmed: 25709118
Nature. 2017 Nov 16;551(7680):384-388
pubmed: 29144447
Br J Haematol. 2020 Feb;188(3):404-412
pubmed: 31468521
PLoS Genet. 2008 Oct;4(10):e1000227
pubmed: 18927631
Blood. 2014 Oct 23;124(17):2705-12
pubmed: 25224413
Br J Haematol. 2017 Feb;176(4):609-617
pubmed: 27905102
Leukemia. 2020 Dec;34(12):3388-3392
pubmed: 32655143
JCO Precis Oncol. 2019;3:
pubmed: 31663066
Nucleic Acids Res. 2003 Jun 15;31(12):3101-13
pubmed: 12799438
Eur J Haematol. 2000 Feb;64(2):71-9
pubmed: 10997326
Leukemia. 2014 Feb;28(2):411-3
pubmed: 24025691
Mol Cell. 2017 May 4;66(3):306-319
pubmed: 28475867
FEBS Lett. 2019 Oct;593(20):2817-2839
pubmed: 31531979
J Clin Oncol. 2006 Aug 20;24(24):3895-903
pubmed: 16921040
Nat Genet. 1999 Jan;21(1):103-7
pubmed: 9916800
Cell Rep. 2020 Sep 1;32(9):108093
pubmed: 32877675
Nat Commun. 2019 Aug 2;10(1):3475
pubmed: 31375673
Blood. 2011 Jan 13;117(2):403-11
pubmed: 20940414
Dev Cell. 2020 Jul 20;54(2):239-255
pubmed: 32693057
Nucleic Acids Res. 2016 Jul 8;44(W1):W147-53
pubmed: 27190236
Haematologica. 2014 Apr;99(4):613-9
pubmed: 24688109
Oncotarget. 2018 Feb 16;9(23):16437-16450
pubmed: 29662657
Metabolomics. 2015;11(6):1815-1833
pubmed: 26491425
Blood Cancer J. 2020 Aug 14;10(8):83
pubmed: 32801296
Cell Stem Cell. 2014 Oct 2;15(4):507-522
pubmed: 25158935
Nat Protoc. 2016 Oct;11(10):1889-907
pubmed: 27606777
Blood. 2017 Mar 23;129(12):1627-1635
pubmed: 28159738
Leuk Res. 2014 Dec;38(12):1381-91
pubmed: 25444075
Leukemia. 2018 Dec;32(12):2546-2557
pubmed: 30275526
J Cell Biol. 2018 Jul 2;217(7):2247-2259
pubmed: 29760106
Mol Cell. 2016 Jun 2;62(5):695-711
pubmed: 27259202
Front Oncol. 2019 Jan 29;9:16
pubmed: 30761268
Clin Cancer Res. 2017 Jun 15;23(12):3025-3034
pubmed: 27881579
Exp Hematol Oncol. 2020 Jan 6;9:2
pubmed: 31921515
Cell Stem Cell. 2014 May 1;14(5):673-88
pubmed: 24792119
Clin Epigenetics. 2016 Jun 21;8:71
pubmed: 27330573
Cancer Cell. 2010 May 18;17(5):427-42
pubmed: 20478526
Oncotarget. 2017 Apr 25;8(17):28812-28825
pubmed: 28427179
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Blood. 2014 Feb 6;123(6):829-36
pubmed: 24363399
Blood Adv. 2020 Mar 10;4(5):970-982
pubmed: 32150613
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Curr Cancer Drug Targets. 2013 May;13(4):379-99
pubmed: 23517596
Science. 2009 May 22;324(5930):1076-80
pubmed: 19461003
Genome Biol. 2019 Dec 16;20(1):278
pubmed: 31842956
Nat Chem Biol. 2020 Jun;16(6):620-629
pubmed: 32444835
Mol Cell Biol. 2005 Jun;25(11):4727-41
pubmed: 15899874
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Leukemia. 2018 Aug;32(8):1856-1860
pubmed: 29535430
PLoS One. 2017 Aug 16;12(8):e0183228
pubmed: 28813537
Oncotarget. 2018 Jun 12;9(45):27882-27894
pubmed: 29963245
Biomark Insights. 2019 May 08;14:1177271919846454
pubmed: 31105426
Leukemia. 2014 Jan;28(1):78-87
pubmed: 24045501
Ann Hematol. 2018 Nov;97(11):2025-2038
pubmed: 30084010
Blood. 2017 Mar 23;129(12):1586-1594
pubmed: 28159737
J Clin Invest. 2014 Jan;124(1):47-55
pubmed: 24382389
FEBS Lett. 2000 Jul 7;476(3):118-23
pubmed: 10913597
Blood. 2012 Sep 6;120(10):2076-86
pubmed: 22753872
Nature. 2003 May 22;423(6938):456-61
pubmed: 12732850
Eur J Haematol. 2013 Sep;91(3):219-27
pubmed: 23679560
Genes Dev. 2019 Nov 1;33(21-22):1460-1474
pubmed: 31676734
Clin Cancer Res. 2009 Jun 15;15(12):3938-46
pubmed: 19509174
Signal Transduct Target Ther. 2019 Dec 17;4:62
pubmed: 31871779
Blood. 2019 Feb 7;133(6):521-529
pubmed: 30545832
Nat Rev Genet. 2011 Feb;12(2):123-35
pubmed: 21221116
Leukemia. 2018 May;32(5):1094-1105
pubmed: 29487386
Nat Rev Cancer. 2016 Nov;16(11):694-707
pubmed: 27634449
Mol Cell. 2004 Oct 8;16(1):93-105
pubmed: 15469825
Oncotarget. 2016 Mar 22;7(12):14172-87
pubmed: 26871476
Leukemia. 2021 Apr;35(4):1023-1036
pubmed: 32770088
Cell Stem Cell. 2014 Jul 3;15(1):37-50
pubmed: 24813857
Mol Cell Biol. 2006 Mar;26(5):1839-49
pubmed: 16479003
Nat Med. 2019 Jan;25(1):103-110
pubmed: 30510255